Clinical Trials
12 trialsNCT03964506 2026-06-03
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
University of Rochester
Phase EARLY_PHASE1 Recruiting
NCT03422731 2026-04-15
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
City of Hope Medical Center
Phase EARLY_PHASE1 Recruiting
NCT05035706 2026-03-05
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03568994 2026-01-27
ATACC AML
Baylor College of Medicine
Phase EARLY_PHASE1 Completed
NCT07338357 2026-01-13
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
First Affiliated Hospital of Guangxi Medical University
Phase EARLY_PHASE1 Not yet recruiting
NCT06765876 2026-01-12
UHKT-CAR123-01
Institute of Hematology and Blood Transfusion, Czech Republic
Phase EARLY_PHASE1 Recruiting
NCT07059975 2025-11-04
UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML
Baylor College of Medicine
Phase EARLY_PHASE1 Recruiting
NCT07201727 2025-10-01
CD123+CLL-1 CAR-T Sequential Infusion With CD7 CAR-T and Bridging to Allo-HSCT for Relapsed/Refractory Acute Myeloid Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Not yet recruiting
NCT06398457 2025-09-26
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Recruiting
NCT07144020 2025-08-27
Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT07126782 2025-08-17
The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1 Recruiting
NCT03957915 2025-08-06
INA03
Institut Paoli-Calmettes
Phase EARLY_PHASE1 Completed